Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting

Bioconjugate Chemistry

Volumn 25, Issue 12, 2014, Pages 2144-2156

  Stefan, Nikolas ^a,b,c   Zimmermann, Martina ^a   Simon, Manuel ^a,b,d   Zangemeister Wittke, Uwe ^a,b   Plückthun, Andreas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c NBE Therapeutics AG   (Switzerland)

^d ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; CYTOTOXICITY; METABOLITES;

ANKYRIN REPEATS; CELL-BINDING DOMAIN; CIRCULATION HALF-LIFES; FUSION TOXINS; LONG CIRCULATIONS; PEGYLATION; PRODRUGS; PSEUDOMONAS EXOTOXIN A; REPEAT PROTEINS; TUMOR-TARGETING;

TUMORS;

ALKYNE; ANTINEOPLASTIC AGENT; AZIDE; DESIGNED ANKYRIN REPEAT PROTEIN EC1 PSEUDOMONAS EXOTOXIN A FUSION PROTEIN; EPITHELIAL CELL ADHESION MOLECULE; MACROGOL; PRODRUG; PROTEINASE; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG; 3C PROTEASES; ANKYRIN; BACTERIAL TOXIN; CELL ADHESION MOLECULE; CYSTEINE PROTEINASE; EPCAM PROTEIN, HUMAN; EXOTOXIN; HYBRID PROTEIN; MACROGOL DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; TUMOR ANTIGEN; VIRULENCE FACTOR; VIRUS PROTEIN;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL VIABILITY; CHEMICAL ENGINEERING; CIRCULATION TIME; CLICK CHEMISTRY; CONJUGATION; CONTROLLED STUDY; CYCLOADDITION; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; FEMALE; HT 29 CELL LINE; HUMAN; HUMAN CELL; IC50; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; RHINOVIRUS; SITE DIRECTED MUTAGENESIS; ANIMAL; BINDING SITE; C57BL MOUSE; CHEMISTRY; DRUG DESIGN; GENETICS; HALF LIFE TIME; METABOLISM; TUMOR CELL LINE;

BACTERIA (MICROORGANISMS); MUS; PSEUDOMONAS EXOTOXIN; RHINOVIRUS;

ADP RIBOSE TRANSFERASES; ANIMALS; ANKYRIN REPEAT; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BACTERIAL TOXINS; BINDING SITES; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CLICK CHEMISTRY; CYSTEINE ENDOPEPTIDASES; DRUG DESIGN; EXOTOXINS; FEMALE; HALF-LIFE; HUMANS; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS; PRODRUGS; RECOMBINANT FUSION PROTEINS; VIRAL PROTEINS; VIRULENCE FACTORS;

EID: 84918536578     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc500468s     Document Type: Article

References (43)

1. FitzGerald, D. J., Wayne, A. S., Kreitman, R. J., and Pastan, I. (2011) Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res. 71, 6300-9.
2. Pastan, I., Hassan, R., Fitzgerald, D. J., and Kreitman, R. J. (2006) Immunotoxin therapy of cancer. Nat. Rev. Cancer 6, 559-65.
3. Weldon, J. E., and Pastan, I. (2011) A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 278, 4683-4700.
4. Simon, M., Stefan, N., Plückthun, A., and Zangemeister-Wittke, U. (2013) Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy. Expert Opin. Drug Delivery 10, 451-68.
5. Martin-Killias, P., Stefan, N., Rothschild, S., Plückthun, A., and Zangemeister-Wittke, U. (2011) A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin. Cancer. Res. 17, 100-110.
6. Boersma, Y. L., and Plückthun, A. (2011) DARPins and other repeat protein scaffolds: advances in engineering and applications. Curr. Opin. Biotechnol. 22, 849-57.
7. Binz, H. K., Stumpp, M. T., Forrer, P., Amstutz, P., and Plückthun, A. (2003) Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J. Mol. Biol. 332, 489-503.
8. Simon, M., Zangemeister-Wittke, U., and Plückthun, A. (2012) Facile double-functionalization of Designed Ankyrin Repeat Proteins using click and thiol chemistries. Bioconjugate Chem. 23, 279-286.
9. Spizzo, G., Fong, D., Wurm, M., Ensinger, C., Obrist, P., Hofer, C., Mazzoleni, G., Gastl, G., and Went, P. (2011) EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J. Clin. Pathol. 64, 415-20.
10. Went, P., Lugli, A., Meier, S., Bundi, M., Mirlacher, M., Sauter, G., and Dirnhofer, S. (2004) Frequent EpCAM protein expression in human carcinomas. Hum. Pathol. 35, 122-128.
11. Simon, M., Stefan, N., Borsig, L., Plückthun, A., and Zangemeister-Wittke, U. (2014) Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation. Mol. Cancer Ther. 13, 375-85.
12. Hassan, R., Bullock, S., Premkumar, A., Kreitman, R. J., Kindler, H., Willingham, M. C., and Pastan, I. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus i.v. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer. Res. 13, 5144-9.
13. Schümann, J., Angermüller, S., Bang, R., Lohoff, M., and Tiegs, G. (1998) Acute hepatotoxicity of Pseudomonas aeruginosa exotoxin A in mice depends on T cells and TNF. J. Immunol. 161, 5745-54.
14. Kreitman, R. J., Wilson, W. H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D. J., and Pastan, I. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. New Engl. J. Med. 345, 241-7.
15. Kreitman, R. J., and Pastan, I. (1995) Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. Biochem. J. 307 (Pt 1), 29-37.
16. Weldon, J. E., Xiang, L., Chertov, O., Margulies, I., Kreitman, R. J., FitzGerald, D. J., and Pastan, I. (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 113, 3792-800.
17. Weldon, J. E., Xiang, L., Zhang, J., Beers, R., Walker, D. A., Onda, M., Hassan, R., and Pastan, I. (2013) A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol. Cancer Ther. 12, 48-57.
18. Onda, M., Beers, R., Xiang, L., Lee, B., Weldon, J. E., Kreitman, R. J., and Pastan, I. (2011) Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc. Natl. Acad. Sci. U.S.A. 108, 5742-7.
19. Mazor, R., Vassall, A. N., Eberle, J. A., Beers, R., Weldon, J. E., Venzon, D. J., Tsang, K. Y., Benhar, I., and Pastan, I. (2012) Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc. Natl. Acad. Sci. U.S.A. 109, E3597-603.
20. Onda, M., Nagata, S., FitzGerald, D. J., Beers, R., Fisher, R. J., Vincent, J. J., Lee, B., Nakamura, M., Hwang, J., Kreitman, R. J., Hassan, R., and Pastan, I. (2006) Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J. Immunol. 177, 8822-34.
21. Alconcel, S. N. S., Baas, A. S., and Maynard, H. D. (2011) FDA-approved poly(ethylene glycol)-protein conjugate drugs. Polym. Chem. 2, 1442.
22. Veronese, F. M., and Pasut, G. (2005) PEGylation, successful approach to drug delivery. Drug Discovery Today 10, 1451-1458.
23. Benhar, I., Wang, Q. C., Fitzgerald, D., and Pastan, I. (1994) Pseudomonas exotoxin-a mutants - replacement of surface-exposed residues in domain-III with cysteine residues that can be modified with polyethylene-glycol in a site-specific manner. J. Biol. Chem. 269, 13398-13404.
24. Tsutsumi, Y., Onda, M., Nagata, S., Lee, B., Kreitman, R. J., and Pastan, I. (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. U.S.A. 97, 8548-8553.
25. Filpula, D., Yang, K., Basu, A., Hassan, R., Xiang, L., Zhang, Z., Wang, M., Wang, Q. C., Ho, M., Beers, R., Zhao, H., Peng, P., Zhou, J., Li, X., Petti, G., Janjua, A., Liu, J., Wu, D., Yu, D., Zhang, Z., Longley, C., FitzGerald, D., Kreitman, R. J., and Pastan, I. (2007) Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjugate Chem. 18, 773-84.
26. Harris, J. M., and Chess, R. B. (2003) Effect of PEGylation on pharmaceuticals. Nat. Rev. Drug Discovery 2, 214-21.
27. Bailon, P., and Won, C. Y. (2009) PEG-modified biopharmaceuticals. Expert Opin. Drug Delivery 6, 1-16.
28. Stefan, N., Martin-Killias, P., Wyss-Stoeckle, S., Honegger, A., Zangemeister-Wittke, U., and Plückthun, A. (2011) DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J. Mol. Biol. 413, 826-843.
29. Wang, A., Winblade Nairn, N., Johnson, R. S., Tirrell, D. A., and Grabstein, K. (2008) Processing of N-terminal unnatural amino acids in recombinant human interferon-beta in Escherichia coli. Chem-BioChem 9, 324-330.
30. Jorgensen, R., Wang, Y., Visschedyk, D., and Merrill, A. R. (2008) The nature and character of the transition state for the ADP-ribosyltransferase reaction. EMBO Rep. 9, 802-9.
31. Kurfürst, M. M. (1992) Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal. Biochem. 200, 244-248.
32. Kubetzko, S., Sarkar, C. A., and Plückthun, A. (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism. Mol. Pharmacol. 68, 1439-1454.
33. Wang, Q. C., Pai, L. H., Debinski, W., FitzGerald, D. J., and Pastan, I. (1993) Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. Cancer Res. 53, 4588-94.
34. Liu, W., Onda, M., Lee, B., Kreitman, R. J., Hassan, R., Xiang, L., and Pastan, I. (2012) Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc. Natl. Acad. Sci. U.S.A. 109, 11782-7.
35. Tsubery, H., Mironchik, M., Fridkin, M., and Shechter, Y. (2004) Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J. Biol. Chem. 279, 38118-24.
36. Olson, E. S., Jiang, T., Aguilera, T. A., Nguyen, Q. T., Ellies, L. G., Scadeng, M., and Tsien, R. Y. (2010) Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl. Acad. Sci. U.S.A. 107, 4311-6.
37. Jiang, T., Olson, E. S., Nguyen, Q. T., Roy, M., Jennings, P. A., and Tsien, R. Y. (2004) Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. U.S.A. 101, 17867-72.
38. Terada, T., Iwai, M., Kawakami, S., Yamashita, F., and Hashida, M. (2006) Novel PEG-matrix metalloproteinase-2 cleavable peptidelipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J. Controlled Release 111, 333-42.
39. Harris, T. J., von Maltzahn, G., Lord, M. E., Park, J. H., Agrawal, A., Min, D. H., Sailor, M. J., and Bhatia, S. N. (2008) Protease-triggered unveiling of bioactive nanoparticles. Small 4, 1307-12.
40. Hatakeyama, H., Akita, H., Kogure, K., Oishi, M., Nagasaki, Y., Kihira, Y., Ueno, M., Kobayashi, H., Kikuchi, H., and Harashima, H. (2007) Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 14, 68-77.
41. Malcolm, B. A. (1995) The picornaviral 3C proteinases: cysteine nucleophiles in serine proteinase folds. Protein Sci. 4, 1439-45.
42. Salis, H. M., Mirsky, E. A., and Voigt, C. A. (2009) Automated design of synthetic ribosome binding sites to control protein expression. Nat. Biotechnol. 27, 946-50.
43. Krissinel, E., and Henrick, K. (2007) Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-97.